Hypothyroidism related to immunotherapy in elderly adults: Analysis of a Colombian oncology cohort. Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) ...

Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1- or SMARCA4-deficient tumors: PEPN2121. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

The American Academy of Pediatrics presents updated guidance for the treatment of children with atopic dermatitis (AD).

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

Melanie Hilgers, a dermatologist in Luxembourg, treats many sufferers in her practice, in which she often sees a combination ...

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in first draft guidance, citing uncertainties with evidence. It’s common for ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to ...

Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...